Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Inc. Announces Consolidated Earnings Results for Three Quarters Ended December 31, 2016

01/30/2017 | 10:06pm EDT

Astellas Pharma Inc. announced consolidated earnings results for three quarters ended December 31, 2016. For the nine months, the company reported sales of JPY 1,005,587 million against JPY 10,656,666 million a year ago. Core operating profit was JPY 2,418,370 million against JPY 2,338,630 million a year ago. Core profit for the period was JPY 1,771,890 million against JPY 1,693,790 million a year ago. Basic core earnings per share were JPY 83.62 against JPY 78.16 a year ago. Sales in the first nine months of fiscal year 2016 decreased by 5.6% compared to those in the corresponding period of the previous fiscal year. Sales decreased due to the impact of foreign exchange as well as the impact of the NHI drug price revision in Japan enforced in April 2016. On a constant currency basis, however, sales increased by approximately 3% year-on-year.


ę S&P Capital IQ 2017
All news about ASTELLAS PHARMA INC.
09/23ASTELLAS PHARMA : Tohoku University and Astellas Establish Second Phase of Comprehensive I..
PU
09/23ASTELLAS PHARMA INC. : will present 12-week results (S-13) from the pivotal Phase 3 SKYLIG..
AQ
09/22Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic..
AQ
09/22Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2Ö Trial in Ora..
CI
09/22ASTELLAS PHARMA : to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ ..
PU
09/21ASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
AQ
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
More news
Financials
Sales 2022 1 325 B 11 963 M 11 963 M
Net income 2022 194 B 1 756 M 1 756 M
Net cash 2022 478 B 4 312 M 4 312 M
P/E ratio 2022 18,0x
Yield 2022 2,63%
Capitalization 3 525 B 31 844 M 31 831 M
EV / Sales 2022 2,30x
EV / Sales 2023 1,94x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 902,50 JPY
Average target price 2 451,54 JPY
Spread / Average Target 28,9%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.19.35%31 844
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037